Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_4
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Withdrawn2
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

unknown125%
withdrawn250%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
withdrawnphase_4

Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD

NCT00291408
withdrawn

Biomarkers of iNOS Activity in COPD, Asthma, Healthy Control

NCT00159302
unknownphase_1

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

NCT02584751
completednot_applicable

Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia

NCT01155115

Clinical Trials (4)

Showing 4 of 4 trials
NCT00291408Phase 4

Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD

Withdrawn
NCT00159302

Biomarkers of iNOS Activity in COPD, Asthma, Healthy Control

Withdrawn
NCT02584751Phase 1

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

Unknown
NCT01155115Not Applicable

Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4